Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results
August 07, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Presented Preliminary Clinical Data on RX-3117 in Bladder Cancer at the American Society of Clinical Oncologists (ASCO) Annual Meeting Strengthened Financial Position with a $10 million Registered...
Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117
July 10, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., July 10, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Announces $10 Million Registered Direct Offering
June 07, 2017 08:50 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., June 07, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into definitive agreements with institutional investors to purchase...
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
June 04, 2017 09:00 ET
|
Rexahn Pharmaceuticals
RX-3117 Monotherapy Increased Progression Free Survival and Showed Evidence of Tumor Shrinkage in Patients with Metastatic Bladder Cancer Resistant to Gemcitabine who had Failed on Multiple Prior...
Rexahn Effects 1-for-10 Reverse Stock Split
May 05, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., May 05, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) (“Rexahn” or the “Company”), a clinical stage biopharmaceutical company developing innovative, targeted...
Rexahn Announces 1-for-10 Reverse Stock Split
April 13, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the...
Rexahn Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Corporate Update
February 27, 2017 09:00 ET
|
Rexahn Pharmaceuticals
Progressed Three Novel Targeted Anti-Cancer Therapies in Clinical Development Completed stage 1 and initiated stage 2 of Phase IIa clinical trial of RX-3117 in Relapsed and Refractory Metastatic...